

Third Meeting of the Quadripartite Technical Group on the Economics of Antimicrobial Resistance (QTG-EA)

6 November 2023, 13.30-15.30 CET

MEETING REPORT

Chair: *Jean-Pierre Nyemazi, Lead for the Core Team on economics of AMR within the Quadripartite Joint Secretariat on AMR*

QTG-EA member participants: *Amna Siddiqui, André Luiz de Abreu, Angela Mazimba, Argaw Ambelu, Darwin Bandow, Djordje Gikic, Dominic Moran, Guillaume Lhermie, Hadeer Swedan, Holy Akwar, Josephine Gakii, Julie Robotham, Justice Nonvignon, Luca Guardabassi, Nichola Naylor, Olga Perovic, Raymond Oppong, Rosa Rodriguez-Monguio, Wei Wang, Yasser Mahmmod*

Presenters: *Chantal Morel, Michele Cecchini, Federico Cairolì*

Relevant staff from the Quadripartite organizations: *Chinyere Okoro, Myfawny Hernandez, Eleanor Raj, Aitziber Echeverria, Alejandro Acosta, Holy Teneg Akwar*

Process of the meeting: The third official meeting of the Quadripartite Technical Group on Antimicrobial Resistance (QTG-EA) was held virtually on 6 November 2023 (13h30-15h30 Central European Time). The meeting was chaired by Jean-Pierre Nyemazi, from the Quadripartite Joint Secretariat on AMR. Dr Nyemazi reiterated the importance of this work in the run up to the United Nations General Assembly High-Level Meeting (UNGA HLM) on AMR in September 2024.

- 1. Progress update on Quadripartite economic work:** Dr Chantal Morel presented the overall progress update of Quadripartite work in developing the economic case for tackling AMR. Of note were that the Inventory of Funders will soon be ready for circulation to countries to help target NAP funding applications to external donors. Discussions with regions are also taking place to help facilitate economic studies and AMR investment case development that could further shape funding applications.
- 2. Economic burden of AMR:** Dr Michele Cecchini from OECD presented findings from the Business-as-Usual study. Several methodological points were addressed, including data sources, key assumptions, and region-specific factors. Improvements since the second QTG-EA meeting were outlined, including expanded regional inclusion, a finalization of the labour market module, projections of AMR rates, and model calibration. Quasi-final analyses were shared with the group, before opening the floor to expert discussion. Q&A topics included data shortages, uncertainty, data availability, and the assumed number of resistant infections. The choice of “replacement” versus “elimination” scenario, as well as the potential misunderstandings that this wording might produce, were also discussed at length. As the latter issue was not resolved, the discussion on the selected counterfactual will continue, with written updates to be circulated.

- 3. Return on investment for AMR intervention:** Dr Federico Cairoli from Triangulate Health Ltd. presented progress updates on the return-on-investment study. From the list of 52 priority AMR interventions, a final 10 interventions have been selected for inclusion based on data availability and coherence with model data requirements. Data gaps were identified, as well as proposed assumptions to account for these gaps. Methodological questions regarding model assumptions were proposed to the experts for discussion, including surrounding the effects of WASH and vaccination coverage. Questions around the latter were not entirely resolved so they will be subject to further discussion and followed up with a written update.
- 4. Closing of the meeting and next steps:** The chair thanked the experts for their productive discussions. He invited them to share more relevant information which could bridge identified data gaps. The fourth meeting of the QTG-EA will be scheduled for either late 2023 or early 2024. A written update will be circulated prior to the meeting.